PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

    (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

    C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NIj5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjnTWM2OD1yLkiyNFI1KM7:TR?= Ml:yV2FPT0WU
UACC-893 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nZTWlEPTB;NT6xPVg5PiEQvF2= NXLl[4VEW0GQR1XS
A427 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnuOIJKSzVyPUWuO|I2PjdizszN MUTTRW5ITVJ?
OCUB-M M3e1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTwTpVtUUN3ME22MlY3OTB{IN88US=> NX;IUJBiW0GQR1XS
SW684 NVS1OHRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPGVGFKSzVyPUeuOVIzPjhizszN MXnTRW5ITVJ?
SK-LMS-1 NGnsN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPITWM2OD17LkCxN|AzKM7:TR?= MY\TRW5ITVJ?
CP50-MEL-B MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX2c3JKSzVyPUmuN|A1OTlizszN MXPTRW5ITVJ?
NCI-H1651 M3HCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PMRWlEPTB;MUCuNFI4PiEQvF2= M2\2WnNCVkeHUh?=
ABC-1 NETZVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDZTWM2OD1zMD6xNFM4KM7:TR?= NXOwb3V5W0GQR1XS
OE19 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPSTWM2OD1zMD6xO|M{KM7:TR?= MoDGV2FPT0WU
DSH1 NVvFRpNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frUmlEPTB;MUCuPFg4QSEQvF2= M1WzU3NCVkeHUh?=
SW13 M33uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFzLkmzNVkh|ryP M1HvV3NCVkeHUh?=
MDA-MB-453 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ywUWlEPTB;MUKuNVYxOyEQvF2= NX21W|Z2W0GQR1XS
647-V NVjYfVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W3eGlEPTB;MUKuN|U5OiEQvF2= NUTCV|NtW0GQR1XS
NCI-H2342 NV;wTGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL5[2tiUUN3ME2xNk4{QTl3IN88US=> NFT5WFNUSU6JRWK=
LB2241-RCC MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nfmlEPTB;MUKuOVc4QSEQvF2= NVfjUZoxW0GQR1XS
UACC-257 NIjOSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;XZWlEPTB;MUOuOFQ2OyEQvF2= MUDTRW5ITVJ?
NCI-H661 NG[zR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu3dpZKSzVyPUGzMlY1PDlizszN MnvYV2FPT0WU
FADU Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC2fI5VUUN3ME2xN{43QTl{IN88US=> NUjx[I5mW0GQR1XS
A2780 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\UepRiUUN3ME2xN{45ODRzIN88US=> MVrTRW5ITVJ?
NCI-H1793 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\6PGlEPTB;MUSuOFA5PSEQvF2= MWTTRW5ITVJ?
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2dGlEPTB;MUWuN|Q3PSEQvF2= NYjw[WRnW0GQR1XS
HGC-27 NFzScnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ESWlEPTB;MU[uNVY1PCEQvF2= M2rBPXNCVkeHUh?=
MMAC-SF MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF5LkO3Nlch|ryP NUXBXJVzW0GQR1XS
Calu-6 NWrNbFg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe0Tlk6UUN3ME2xPE4yPTF|IN88US=> MYHTRW5ITVJ?
HUTU-80 M4K5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInRTYlKSzVyPUG4MlM6PTlizszN NWLs[GxuW0GQR1XS
SAS NFrhVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF6Lk[0OVUh|ryP NXyxW2VDW0GQR1XS
IST-MES1 NUC4RY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXWTWM2OD1zOD62OVA5KM7:TR?= MlLuV2FPT0WU
C3A NH6wPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTHcFZKSzVyPUG4Mlc6OTlizszN MlzKV2FPT0WU
ES3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvlUXVKSzVyPUG4Mlg{PjRizszN NHO5PYxUSU6JRWK=
HSC-2 NXfGRop[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jNRmlEPTB;MUmuOlU1OSEQvF2= NIHQWpZUSU6JRWK=
T47D MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXRbYltUUN3ME2yNE4yPDh3IN88US=> NUKxPHJLW0GQR1XS
EW-7 NWDtelRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M362W2lEPTB;MkCuPFU5QCEQvF2= M3viVnNCVkeHUh?=
LN-405 M2PaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TnPGlEPTB;MkCuPFk3PSEQvF2= MU\TRW5ITVJ?
U031 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlflTWM2OD1{MT60PFAzKM7:TR?= MkDpV2FPT0WU
A549 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPLdGtzUUN3ME2yNU45PDlzIN88US=> MWPTRW5ITVJ?
RMG-I M{LHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfCTWM2OD1{Mj6yOlY5KM7:TR?= M2jQZ3NCVkeHUh?=
BT-474 M3O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ{Lk[1OVEh|ryP NHLOeGRUSU6JRWK=
NB69 M1PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ|LkG1NkDPxE1? NHvu[GpUSU6JRWK=
NB7 NYrQfoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXYNYdiUUN3ME2yOE4yQDhizszN MoX0V2FPT0WU
HCC1569 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDXW|FKSzVyPUK0MlYyOjVizszN NXvuRXY4W0GQR1XS
MEL-JUSO MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLGTWM2OD1{ND62PVA5KM7:TR?= M2rufXNCVkeHUh?=
MDA-MB-175-VII NXy0SolZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTPcGFrUUN3ME2yOU4zPTF5IN88US=> Mn;CV2FPT0WU
HCC1419 NXvFXFJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ3Lk[wNFMh|ryP MlT3V2FPT0WU
Ca9-22 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jMS2lEPTB;MkWuOlQ{OiEQvF2= Mn2yV2FPT0WU
KGN Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ3Lke1OFch|ryP M4HXb3NCVkeHUh?=
LB373-MEL-D MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon4TWM2OD1{Nj6xPVM5KM7:TR?= MUPTRW5ITVJ?
NCI-H1755 M4\ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTSUHo4UUN3ME2yOk45QDRzIN88US=> MUHTRW5ITVJ?
D-423MG NXm4b41XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjrPGNEUUN3ME2yO{4xPzF3IN88US=> MnjTV2FPT0WU
DK-MG NVXnTlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;MOXJKSzVyPUK4Mlc5PDZizszN M13wfnNCVkeHUh?=
NCI-H1623 NUPR[ZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHWZnJkUUN3ME2yPE45OzR{IN88US=> Ml7CV2FPT0WU
KU-19-19 M17VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jLWmlEPTB;MkiuPVk2KM7:TR?= M4PkfXNCVkeHUh?=
C-33-A MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j0XWlEPTB;MkmuNlE6QCEQvF2= Mnv3V2FPT0WU
SCC-4 NH;0WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrKXW5KSzVyPUOwMlM{PTRizszN MnjYV2FPT0WU
MG-63 NXTW[451T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTNyLkW5PVQh|ryP NXnqRmFCW0GQR1XS
LNCaP-Clone-FGC NV;1VWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNzLkS5NlEh|ryP Ml\aV2FPT0WU
CAPAN-1 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqxco5yUUN3ME2zNU42Ojh4IN88US=> M{fRbnNCVkeHUh?=
GI-ME-N NWX0VGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\uV2lEPTB;M{GuOVM2OyEQvF2= NGH6XmNUSU6JRWK=
RERF-LC-MS NHPFSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\nWmlEPTB;M{KuOlc1PyEQvF2= NEezSVFUSU6JRWK=
KLE M3LrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXxN4pKSzVyPUOzMlQ{OzRizszN M2KyTnNCVkeHUh?=
KNS-81-FD Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T4SmlEPTB;M{OuOVAxQCEQvF2= NIXyWINUSU6JRWK=
DOK NFj3dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jobGlEPTB;M{SuOlYyOiEQvF2= NVrQRlJUW0GQR1XS
ACHN NV\HcXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfpOFFqUUN3ME2zOU4yPTh6IN88US=> NWG1NlVjW0GQR1XS
KYSE-520 M3n1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfhVHJKSzVyPUO1MlI{PjFizszN MYjTRW5ITVJ?
SBC-5 NULZPIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\BXoN3UUN3ME2zOU42OTF4IN88US=> MXTTRW5ITVJ?
NCI-H28 NHnySpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PmfmlEPTB;M{WuOlY6PSEQvF2= NXXvNFlGW0GQR1XS
ES7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;rU3BsUUN3ME2zOk4zOjR7IN88US=> MkjpV2FPT0WU
A172 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnGTWM2OD1|Nj60NVg4KM7:TR?= NGXuOYFUSU6JRWK=
UM-UC-3 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN5Lki3OFYh|ryP M2T2THNCVkeHUh?=
LXF-289 NWrGfYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPjTWM2OD1|OD6wNFQ4KM7:TR?= NUHyNWVlW0GQR1XS
KP-4 NGTRcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN6LkS3N|kh|ryP MmfnV2FPT0WU
TE-1 NFTJR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi0RZFrUUN3ME2zPU43PTh7IN88US=> MV\TRW5ITVJ?
G-402 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLre4JUUUN3ME20NE4xPjFizszN NGL1fodUSU6JRWK=
786-0 NFjY[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHnTWM2OD12MD65NFk3KM7:TR?= Mle3V2FPT0WU
K5 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELKZW9KSzVyPUSxMlM3QDZizszN NGO0fVNUSU6JRWK=
SK-N-DZ M3fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRzLkO4NlMh|ryP MlvVV2FPT0WU
OVCAR-4 NYDEblZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jFTmlEPTB;NEGuO|U3QCEQvF2= M2TrS3NCVkeHUh?=
T84 M1jUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXIdFlKSzVyPUSyMlEzPjNizszN Mnv1V2FPT0WU
GCIY NULRXGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR|LkC4NFMh|ryP M1PTfHNCVkeHUh?=
BB49-HNC NFj3UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRSmlEPTB;NEOuN|M1QCEQvF2= MljMV2FPT0WU
SNU-C2B Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKTWM2OD12Mz62OFM3KM7:TR?= MnfhV2FPT0WU
TE-6 NX3TbZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i3VWlEPTB;NEOuPFg6PCEQvF2= MlzJV2FPT0WU
23132-87 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTjcFFTUUN3ME20OE4zQTd6IN88US=> M1HheHNCVkeHUh?=
DMS-53 M1G4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR2LkOzPFQh|ryP NHjVfGNUSU6JRWK=
ONS-76 M4C3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4NIt1UUN3ME20OE44PjZzIN88US=> NF3seHlUSU6JRWK=
DMS-273 M3zpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL2NW1KSzVyPUS0Mlk1OyEQvF2= NXLDO2VWW0GQR1XS
COLO-824 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[3c5hKSzVyPUS1Mlg4PzVizszN MXvTRW5ITVJ?
DMS-114 NXS2TnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\DNXpKSzVyPUS1Mlg6OjdizszN NYrreoo4W0GQR1XS
YKG-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD12Nj6wN|U2KM7:TR?= NFHQfXdUSU6JRWK=
RH-18 NVq1enFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTJNJJKSzVyPUS2MlM4OzNizszN NUi4fZYyW0GQR1XS
NCI-H1355 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGTGRKSzVyPUS2MlYyQCEQvF2= NIHuN2hUSU6JRWK=
NCI-H2170 NITVPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfSRYJKSzVyPUS3Mlc2QDRizszN M{nXb3NCVkeHUh?=
OC-314 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nlWWlEPTB;NEeuPFQ4QCEQvF2= MUjTRW5ITVJ?
NCI-H2030 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnxUHdKSzVyPUS3Mlg6ODZizszN MmXWV2FPT0WU
22RV1 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzpV4F7UUN3ME20O{46ODF3IN88US=> MkXsV2FPT0WU
G-401 NF\oOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTR6LkS0NVUh|ryP MlHaV2FPT0WU
YAPC M2Txb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR7LkiwO|Mh|ryP M3\qS3NCVkeHUh?=
SW1573 M1zOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVyLkK0N|Uh|ryP NX[zbHBtW0GQR1XS
COLO-792 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHMTWM2OD13MD62NlM4KM7:TR?= M3vib3NCVkeHUh?=
KNS-62 NXH0WlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvRbIRKSzVyPUWwMlc2ODhizszN NVm0NGp6W0GQR1XS
NB5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQTW9WUUN3ME21NU41PTB7IN88US=> NFP6UXZUSU6JRWK=
CP66-MEL NUKxXWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn2UHdKSzVyPUWxMlY1ODhizszN MYjTRW5ITVJ?
CaR-1 M1\ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;NPGRKSzVyPUWyMlA3ODZizszN NF;3UZpUSU6JRWK=
CAL-54 M2DYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPRPIZKSzVyPUWyMlEyODJizszN MoLwV2FPT0WU
8305C MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTV{LkOxOUDPxE1? NYTxdZZoW0GQR1XS
Calu-3 NXX6OpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTV{LkO3N|Mh|ryP M1;1NnNCVkeHUh?=
AU565 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPZTWM2OD13Mj61OVA6KM7:TR?= MVXTRW5ITVJ?
CW-2 NYDucXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTWTWM2OD13Mj64OlU1KM7:TR?= NEf5SXhUSU6JRWK=
BEN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTV|Lke4OlIh|ryP NVXnPYRxW0GQR1XS
NCI-H1975 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWKyZZkyUUN3ME21N{45QTZ4IN88US=> MoLxV2FPT0WU
HCT-116 NXLtbJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrXTWM2OD13ND6wN|I4KM7:TR?= M3TrNHNCVkeHUh?=
SH-4 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDxR3o{UUN3ME21OE4yOzhizszN NIHDTlJUSU6JRWK=
NCI-H1693 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTV2LkKxNFMh|ryP MnviV2FPT0WU
BPH-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTV3LkK4PVIh|ryP MojzV2FPT0WU
CAMA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfmNWZsUUN3ME21OU45OTF4IN88US=> NIj5WY9USU6JRWK=
A388 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTV4LkC5PFUh|ryP NWnkPGRxW0GQR1XS
C2BBe1 NUXu[otlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLNepBLUUN3ME21Ok4zPjN2IN88US=> MV7TRW5ITVJ?
GAMG NWLsfXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj0RnJKSzVyPUW2MlU6PTVizszN M4fkSXNCVkeHUh?=
MKN28 M{LnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HQSGlEPTB;NU[uPFAyOyEQvF2= M1jHNHNCVkeHUh?=
VA-ES-BJ NUTQVmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O2NGlEPTB;NU[uPFc1PSEQvF2= MXzTRW5ITVJ?
HuCCT1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX2TWM2OD13Nz6wOFkzKM7:TR?= MkXWV2FPT0WU
BFTC-905 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT0TWM2OD13Nz6yPFk5KM7:TR?= MmCzV2FPT0WU
LS-123 M3zoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7iTWM2OD13Nz61OlY5KM7:TR?= MVzTRW5ITVJ?
LB996-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0d4tKSzVyPUW4MlAzQDdizszN NYXwXHVxW0GQR1XS
NCI-H1048 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTV6LkKxPFgh|ryP MV7TRW5ITVJ?
COR-L105 NVLyZlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD13OD63N|M4KM7:TR?= MXLTRW5ITVJ?
OVCAR-8 M3y5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTV7LkG3NVYh|ryP NUXa[mNRW0GQR1XS
SK-N-FI NEn0WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[xNXFKSzVyPUW5MlMzODdizszN NEHZV3VUSU6JRWK=
MES-SA MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nlPWlEPTB;NUmuOFUxQSEQvF2= MYjTRW5ITVJ?
SCC-9 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEeyT4FKSzVyPUW5MlQ4PTNizszN MkXtV2FPT0WU
EFO-27 NXzTRZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKzdIpjUUN3ME21PU46PDNizszN NFjJTo9USU6JRWK=
GT3TKB MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL6TWM2OD14MD62NFQ5KM7:TR?= M{fzWnNCVkeHUh?=
HCC38 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DHNmlEPTB;NkGuOFM4QSEQvF2= M3\tPHNCVkeHUh?=
MLMA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXsO|hKSzVyPU[xMlYyPjNizszN NWXZWGdCW0GQR1XS
D-566MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUNmlEPTB;NkOuOVIzPCEQvF2= M3;ROnNCVkeHUh?=
SF295 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPMb45KSzVyPU[zMlY3PTVizszN MnLaV2FPT0WU
ES4 NX;sTFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTZ2LkS3NVkh|ryP NV\3UohnW0GQR1XS
CAKI-1 NGDKOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQU2tKSzVyPU[0MlU4OjFizszN Mn;0V2FPT0WU
OAW-28 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV25dWxEUUN3ME22OE46PjR5IN88US=> MXfTRW5ITVJ?
NCI-H460 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTZ3LkC4PVch|ryP NWrpUXUyW0GQR1XS
JAR MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonLTWM2OD14NT61OVE3KM7:TR?= M{K1TnNCVkeHUh?=
SNU-449 NF3DR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH4N5lKSzVyPU[1Mlc3OTZizszN M2TkR3NCVkeHUh?=
D-392MG MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GxR2lEPTB;NkWuPVQ{PCEQvF2= MYDTRW5ITVJ?
EW-22 NEXMNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrTJZKSzVyPU[2MlM6PSEQvF2= MkfZV2FPT0WU
GCT MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCyTWM2OD14Nz6wOFQ{KM7:TR?= MYrTRW5ITVJ?
NOS-1 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\iTWM2OD14Nz62PFY4KM7:TR?= M{HyOXNCVkeHUh?=
RH-1 M2fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZ6LkW1OVkh|ryP MV3TRW5ITVJ?
HuH-7 NFLZSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLGTWM2OD14OT6xNFAzKM7:TR?= NHzIO5ZUSU6JRWK=
NUGC-3 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkNGNUUUN3ME23NE46PjR2IN88US=> MljJV2FPT0WU
IST-SL1 M1fLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvYTotKSzVyPUexMlI{OjRizszN NVLpdmRqW0GQR1XS
SHP-77 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XPc2lEPTB;N{KuNVE6KM7:TR?= NIe4SZdUSU6JRWK=
SW1116 NFfVXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW1eFM3UUN3ME23Nk4yPDB5IN88US=> M3Hr[nNCVkeHUh?=
LK-2 NVHGZVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvFTWM2OD15Mj64OlEzKM7:TR?= NIDOeodUSU6JRWK=
U-2-OS MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTd|LkG4Nlgh|ryP NGPvb3dUSU6JRWK=
KYSE-150 NXOwUXJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\SNHdKSzVyPUezMlYyOThizszN NFHSNlVUSU6JRWK=
U251 NYW2OVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOwTWM2OD15Mz64NVY5KM7:TR?= NF32cIpUSU6JRWK=
HT-1080 NGOz[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\YeWlEPTB;N{SuNlU4PCEQvF2= MXHTRW5ITVJ?
NCI-H1437 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTSN|Z5UUN3ME23OE43OzJ4IN88US=> M1zYfXNCVkeHUh?=
HPAF-II NYnzPGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfsNGxtUUN3ME23OE43PDF3IN88US=> NEnTbmJUSU6JRWK=
Becker MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTd3LkGxNFUh|ryP MX;TRW5ITVJ?
PANC-10-05 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j3XmlEPTB;N{WuNlg3PSEQvF2= MnvCV2FPT0WU
TYK-nu NWixdlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;DbmlEPTB;N{WuN|ExOiEQvF2= M{mwbXNCVkeHUh?=
SKG-IIIa MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULvNmVYUUN3ME23OU4{OzRzIN88US=> Mm\kV2FPT0WU
NCI-H1993 NIO3XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITwTIdKSzVyPUe1Mlc{QTdizszN Mn\pV2FPT0WU
S-117 NFu5V|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonsTWM2OD15NT63OVUh|ryP NVXXN2lDW0GQR1XS
HuO9 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH0TWM2OD15Nj6wNFQ5KM7:TR?= NXTBSFh4W0GQR1XS
CAL-51 M3vncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLucVZKSzVyPUe2MlExODZizszN MljFV2FPT0WU
BT-20 M4f1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPvR2RNUUN3ME23Ok4zOTZ6IN88US=> NYfzfVQ{W0GQR1XS
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK5SG1KSzVyPUe2MlMzOTdizszN NUfBWWdHW0GQR1XS
LB1047-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrdWhKSzVyPUe2Mlc3OTlizszN M3OwR3NCVkeHUh?=
ES8 NV;1OmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHkTWM2OD15OD6wNFc{KM7:TR?= NX\HRoxjW0GQR1XS
UMC-11 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwTWM2OD15OD6wPFg1KM7:TR?= NUHOVmx2W0GQR1XS
NCI-H226 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e3TWlEPTB;N{iuNVMyPSEQvF2= MWLTRW5ITVJ?
IGROV-1 M4TKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OzNWlEPTB;N{iuOVU2KM7:TR?= M3HyS3NCVkeHUh?=
BHY NEXRRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7pOIVKSzVyPUe5MlU6PiEQvF2= MYjTRW5ITVJ?
MKN45 M120RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hzc2lEPTB;OECuN|E4PCEQvF2= M{fiNnNCVkeHUh?=
IA-LM NUTlS2p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX0TWM2OD16MD6zOVEyKM7:TR?= Ml60V2FPT0WU
WM-115 NXXJeFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrlW4V2UUN3ME24NU41OTF2IN88US=> MVfTRW5ITVJ?
VMRC-RCZ NYDSW3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC4TWM2OD16MT60OFI2KM7:TR?= M3z3TnNCVkeHUh?=
NCI-H2291 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\NVoVvUUN3ME24NU43QDR{IN88US=> MoXzV2FPT0WU
MCF7 NFLtO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LZfGlEPTB;OEOuNlg6PyEQvF2= M{O5NnNCVkeHUh?=
639-V NGW5[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHqTWM2OD16ND62NVI6KM7:TR?= NHjjZ4tUSU6JRWK=
RT4 M3jVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXIT5NKSzVyPUi1MlI1ODNizszN MUTTRW5ITVJ?
NCI-H2405 NILpW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzDTWM2OD16NT6yPVk4KM7:TR?= MWTTRW5ITVJ?
CAL-33 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnhWnBKSzVyPUi1MlY{OTVizszN Ml\nV2FPT0WU
BT-549 M{LUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XURWlEPTB;OEWuPVM5OiEQvF2= NFXvOlRUSU6JRWK=
HT-1197 NYnxUWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HtVWlEPTB;OEiuNVA4PyEQvF2= NH72W5hUSU6JRWK=
G-361 M4DRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfWTWM2OD16OD6xOFc1KM7:TR?= MmTWV2FPT0WU
LS-411N NVHOdm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\Gd2lEPTB;OEmuN|M5QCEQvF2= NF3FU29USU6JRWK=
HT-144 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXUTWM2OD16OT61PVkzKM7:TR?= NUjac41DW0GQR1XS
DJM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;qe3pKSzVyPUi5Mlg5PDVizszN MX;TRW5ITVJ?
CAL-12T NUTxSIJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7TUoFsUUN3ME25NE44QDl3IN88US=> MXXTRW5ITVJ?
MKN7 M3PmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX24cZU1UUN3ME25NU4{PTVzIN88US=> Ml;EV2FPT0WU
HuP-T3 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjWcnJyUUN3ME25Ok4yODB2IN88US=> MoryV2FPT0WU
SK-MG-1 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr5[WZwUUN3ME25Ok4yOzR6IN88US=> M{PVWHNCVkeHUh?=
NCI-H2347 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTl6LkGwOFIh|ryP NHLUWYRUSU6JRWK=
SW872 NIexUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjGTWM2OD1zMECuOFU3KM7:TR?= MoTpV2FPT0WU
COLO-829 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7JXZBKSzVyPUGwNE42PTNizszN MVnTRW5ITVJ?
MC-IXC MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTGT3l4UUN3ME2xNFAvPjF3IN88US=> MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID